Lenacapavir
- All
- News
-
EU Regulator Approves Twice-Yearly Injectable Drug For HIV Prevention
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission.
-
Revolutionary New Drug Offers 99.9% Protection Against HIV
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high costs may limit its global impact.
-
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care
A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug Administration (FDA) approving lenacapavir, a new prototype medication.
-
Anti-HIV Injection Taken Twice A Year Shows 100% Efficacy: Study
The most common adverse effects were injection-site reactions experienced by close to 70 per cent of the participants in the Lenacapavir group.
-
New "Vaccine-Like" HIV Drug Could Cost 1,000 Times Less Than Current Price
A new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated on Tuesday.
-
EU Regulator Approves Twice-Yearly Injectable Drug For HIV Prevention
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission.
-
Revolutionary New Drug Offers 99.9% Protection Against HIV
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high costs may limit its global impact.
-
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care
A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug Administration (FDA) approving lenacapavir, a new prototype medication.
-
Anti-HIV Injection Taken Twice A Year Shows 100% Efficacy: Study
The most common adverse effects were injection-site reactions experienced by close to 70 per cent of the participants in the Lenacapavir group.
-
New "Vaccine-Like" HIV Drug Could Cost 1,000 Times Less Than Current Price
A new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated on Tuesday.
